Fig. 3.
![Fig. 3. Thalidomide reduced myeloma tumor burden only in SCID-hu hosts implanted with human liver. / Sections (stained with hematoxylin and eosin) of decalcified human bones of CMC control (A,C) and thalidomide-treated (B,D) hosts inoculated with myeloma cells from patient 9. Note marked decrease in myeloma infiltration in the section from a host implanted with human liver (SCID-hu B+L, [D]) and no change in the section from SCID-hu B (B) compared with their respective CMC-treated (SCID-hu B+L, [C] and SCID-hu B, [A]) controls.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/100/12/10.1182_blood-2002-03-0939/5/h82323503003.jpeg?Expires=1735853638&Signature=IpHbNJFnwOFgdWn2a~9pVeuxav8rGXiZPJ2E2l62S6nIA5UN090qjdM6RJo7PZfJGkW~7mv6WWisViTBiIzpaHa7k9dcn1ebsgWJtUq2no78q~moNZgzbIByXv6K0-pWidyIm1qrMpk2TQU~uo2NiQt~WmamD38-ef-D5om1VzVUIRK~psoEIVQZDH4zi-ygevlH3wKEGDROD3f8d9SPlCwoVm4-Y81Cx7XZB-Y3qoFUhKCQQ6NSxgDlKW4~a0bLV2MkVA4LQkLUhc03FEorBi7LgX0yUxcy93K2hBEXrn9tj40K9TsrKKgZiK2sS1GJ4KK4eH0WHTBgysFUNLr99g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Thalidomide reduced myeloma tumor burden only in SCID-hu hosts implanted with human liver.
Sections (stained with hematoxylin and eosin) of decalcified human bones of CMC control (A,C) and thalidomide-treated (B,D) hosts inoculated with myeloma cells from patient 9. Note marked decrease in myeloma infiltration in the section from a host implanted with human liver (SCID-hu B+L, [D]) and no change in the section from SCID-hu B (B) compared with their respective CMC-treated (SCID-hu B+L, [C] and SCID-hu B, [A]) controls.
